REGN
Price:
$1007.92
Market Cap:
$109.28B
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carci...[Read more]
Industry
Biotechnology
IPO Date
1991-04-02
Stock Exchange
NASDAQ
Ticker
REGN
According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 26.70. This represents a change of 8.97% compared to the average of 24.50 of the last 4 quarters.
The mean historical PE Ratio of Regeneron Pharmaceuticals, Inc. over the last ten years is 41.75. The current 26.70 PE Ratio has changed 6.29% with respect to the historical average. Over the past ten years (40 quarters), REGN's PE Ratio was at its highest in in the March 2015 quarter at 170.03. The PE Ratio was at its lowest in in the June 2021 quarter at 4.99.
Average
41.75
Median
21.54
Minimum
8.27
Maximum
133.67
Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.47%
Maximum Annual PE Ratio = 133.67
Minimum Annual Increase = -51.75%
Minimum Annual PE Ratio = 8.27
Year | PE Ratio | Change |
---|---|---|
2023 | 23.70 | 33.08% |
2022 | 17.81 | 115.47% |
2021 | 8.27 | -44.13% |
2020 | 14.80 | -23.65% |
2019 | 19.38 | 10.48% |
2018 | 17.54 | -51.75% |
2017 | 36.36 | -23.70% |
2016 | 47.65 | -51.55% |
2015 | 98.35 | -26.43% |
2014 | 133.67 | 85.30% |
The current PE Ratio of Regeneron Pharmaceuticals, Inc. (REGN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
16.59
5-year avg
16.79
10-year avg
41.75
Regeneron Pharmaceuticals, Inc.’s PE Ratio is greater than CRISPR Therapeutics AG (-14.99), less than Novo Nordisk A/S (40.39), less than Sarepta Therapeutics, Inc. (249.31), greater than Intellia Therapeutics, Inc. (-3.49), less than Incyte Corporation (147.66), greater than Alnylam Pharmaceuticals, Inc. (-488.32), greater than United Therapeutics Corporation (14.78), greater than Ultragenyx Pharmaceutical Inc. (-7.96), greater than Apellis Pharmaceuticals, Inc. (-9.89), greater than PTC Therapeutics, Inc. (-6.21), greater than Reata Pharmaceuticals, Inc. (-89.36), greater than Intercept Pharmaceuticals, Inc. (-13.55), less than Krystal Biotech, Inc. (48.03), greater than Madrigal Pharmaceuticals, Inc. (-9.02), greater than BeiGene, Ltd. (-47.00), less than BioMarin Pharmaceutical Inc. (52.01), greater than ImmunoGen, Inc. (-122.93), greater than Prometheus Biosciences, Inc. (-81.93), greater than Arrowhead Pharmaceuticals, Inc. (-4.14), greater than Ionis Pharmaceuticals, Inc. (-15.37),
Company | PE Ratio | Market cap |
---|---|---|
-14.99 | $4.00B | |
40.39 | $523.48B | |
249.31 | $11.88B | |
-3.49 | $1.86B | |
147.66 | $12.68B | |
-488.32 | $36.08B | |
14.78 | $15.84B | |
-7.96 | $4.96B | |
-9.89 | $3.24B | |
-6.21 | $2.99B | |
-89.36 | $6.57B | |
-13.55 | $794.69M | |
48.03 | $5.11B | |
-9.02 | $4.67B | |
-47.00 | $26.14B | |
52.01 | $13.36B | |
-122.93 | $8.73B | |
-81.93 | $9.56B | |
-4.14 | $2.23B | |
-15.37 | $6.07B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Regeneron Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Regeneron Pharmaceuticals, Inc. (REGN)?
What is the highest PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?
What is the 3-year average PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?
What is the 5-year average PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?
How does the current PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN) compare to its historical average?